MedTrace Logo

Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer

NCT01114464 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2016-08-08

No results posted yet for this study

Summary

The aim of this protocol is to study the deleterious impact of adjuvant chemotherapy or neoadjuvant chemotherapy on ovarian reserve in young women suffering from breast cancer. A new relevant ovarian reserve marker, serum Anti-Mullerian Hormone, will be used in order to evaluate precisely the impact of chemotherapy on ovaries during chemotherapy administrations and after during follow-up (24 months). This strategy offers 2 main advantages : no modification of the traditional care of patients (treatment, organisation, follow up …) and use of a non invasive marker (serum). The final objective is to give precise information to patients on their future fertility after remission.

Conditions

  • Ovarian Reserve

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Paul Barrière, MD · Nantes University Hospital

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114464 on ClinicalTrials.gov